The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1
|
A | Alimentary tract and metabolism | |
2
|
A05 | Bile and liver therapy | |
3
|
A05A | Bile therapy | |
4
|
A05AX | Other drugs for bile therapy |
Code | Title | |
---|---|---|
A05AX01 | Piprozolin | |
A05AX02 | Hymecromone | |
A05AX03 | Cyclobutyrol | |
A05AX04 | ||
A05AX05 | ||
A05AX06 | ||
A05AX07 |
Active Ingredient |
---|
Hymecromone is an inhibitor of hyaluronic acid synthesis and has a spasmolytic effect on extrahepatic bile ducts. Hymecromone is an approved prescription drug used for treating biliary spasm. This action takes place through a musculotropic mechanism, without atropinic effects. Increased choleresis is also observed without excitation of gall bladder contraction. |
Maralixibat is a minimally absorbed, reversible, potent, selective inhibitor of the ileal bile acid transporter (IBAT). Maralixibat acts locally in the distal ileum to decrease the reuptake of bile acids and increase the clearance of bile acids through the colon, reducing the concentration of bile acids in the serum. |
Odevixibat is a reversible, potent, selective inhibitor of the ileal bile acid transporter (IBAT). Odevixibat acts locally in the distal ileum to decrease the reuptake of bile acids and increase the clearance of bile acids through the colon, reducing the concentration of bile acids in the serum. The extent of reduction of serum bile acids does not correlate with systemic PK. |
Seladelpar is a peroxisome proliferator-activated receptor delta (PPARδ) agonist, or delpar. PPARδ is a nuclear receptor expressed in the liver and other tissues. PPARδ activation reduces bile acid synthesis in the liver through Fibroblast Growth Factor 21 (FGF21)-dependent downregulation of CYP7A1, the key enzyme for the synthesis of bile acids from cholesterol and by decreasing cholesterol synthesis and absorption. These actions result in lower bile acid exposure in the liver and reduced circulating bile acid levels. |
Document | Type | Information Source | |
---|---|---|---|
BYLVAY Hard capsule | MPI, EU: SmPC | European Medicines Agency (EU) | |
IQIRVO Film-coated tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
IQIRVO Film-coated tablet | MPI, EU: SmPC | European Medicines Agency (EU) | |
KAYFANDA Hard capsule | MPI, EU: SmPC | European Medicines Agency (EU) | |
LIVMARLI Oral solution | MPI, EU: SmPC | European Medicines Agency (EU) |